Doctrim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doctrim

What is Doctrim: Definition and Drug Class Identity

Property Description
Active ingredient Sulphamethoxazole and Trimethoprim
Form Tablet, Oral Suspension, Intravenous Solution
Pharmacological class Combination Antibiotic, Anti-infective Agent
Common use Eliminating bacterial and protozoal infections
Origin Synthetic (Small Molecule)

The pharmaceutical product marketed as Doctrim is a synthetic fixed-dose combination product generically identified as Co-trimoxazole (also abbreviated TMP-SMX). It is formally classified as a combination antibiotic and an anti-infective agent. The importance of this formulation is clinically recognized for its efficacy against a wide range of microbial pathogens. Its status as an essential medicine underscores its importance as a core medication required for a basic health system. Other well-known trade names sharing this exact active formulation include Bactrim and Septra, underscoring its widespread global use.

Composition and Available Forms of Co-trimoxazole

Doctrim is composed of two primary active ingredients: Sulphamethoxazole and Trimethoprim. Sulphamethoxazole is categorized as a sulfonamide antibiotic, and Trimethoprim is an antifolate antibiotic. Pharmacological evidence indicates that combining these two agents produces a synergistic effect that is superior to either component used alone. This small molecule medicine is available in various pharmaceutical preparations to accommodate patient needs. These forms include a conventional tablet or an oral suspension, often preferred for pediatric use, as well as a sterile intravenous solution for parenteral administration via the intravenous route.

Understanding the General Purpose of Doctrim

The general purpose of Doctrim is to efficiently eliminate a broad spectrum of susceptible bacterial and protozoal infections. The primary benefit arises from the highly effective synergistic mechanism achieved by the two agents, which results in a powerful bactericidal outcome. This means the medicine actively kills the infection-causing organisms. This mechanism is applicable in scenarios requiring a robust response, such as certain severe lower respiratory tract infections, providing a definitive approach to clearing the underlying infection.

What side effects are possible with Doctrim?

Possible Side Effects and Safety Information

The official safety profile for Doctrim (Co-trimoxazole) is structured by regulatory bodies to communicate documented adverse effects based on frequency and affected system. All listed effects are derived from authoritative government sources, such as the FDA and EMA prescribing information.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reaction is hyperkalaemia (increased blood potassium), classified as Very Common in official documents. Common reactions often include nausea, diarrhoea, headache, and rash. Less frequent effects are classified as Uncommon or Very Rare.

Classification Examples of Documented Effects
Very Common Hyperkalaemia
Common Nausea, Diarrhoea, Rash
Very Rare Agranulocytosis, Hepatic necrosis, Stevens-Johnson syndrome (SJS)

System and Serious Adverse Reactions

The adverse reactions are categorized across multiple System-Organ Classes (SOC). These include disorders of the Blood and Lymphatic system (e.g., leukopenia, agranulocytosis), the Skin and subcutaneous tissue (e.g., photosensitivity, SJS, Toxic Epidermal Necrolysis (TEN)), and Metabolism and nutrition (e.g., hyponatraemia, hypoglycemia). Serious adverse reactions, while rare, are explicitly documented and include the potentially fatal Severe Cutaneous Adverse Reactions (SCARs), such as SJS and TEN, and serious blood disorders (dyscrasias) like aplastic anaemia.

Population-Specific Safety Considerations

The official label places specific constraints on use in certain populations. The medicine is contraindicated in infants younger than two months of age due to the risk of kernicterus. Elderly patients are officially noted as more susceptible to adverse reactions. Constraints also apply to patients with marked hepatic damage, severe renal insufficiency where monitoring is not possible, and individuals with a known G-6-PD deficiency (risk of haemolysis). The highest risk for SCARs is officially documented as occurring within the first weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents outline the specific manifestations and required emergency actions for a Doctrim (Co-trimoxazole) overdose. Acute presentations commonly include gastrointestinal effects such as nausea, vomiting, and anorexia, combined with neurological symptoms like confusion, dizziness, and headache. Physiological findings may include Hyperkalemia (high blood potassium levels) and Crystalluria.

Overdose can lead to severe, life-threatening systemic outcomes documented in official sources, including circulatory shock, fulminant hepatic necrosis, and fatal complications arising from Severe Cutaneous Adverse Reactions (SCARs) or severe blood dyscrasias.

Due to these risks, immediate medical attention is required upon suspicion of an overdose. The regulatory guidance mandates that emergency services or poison control be contacted immediately if collapse, seizures, severe difficulty breathing, or loss of consciousness occurs. Management is symptomatic and supportive. There is no specific antidote known for acute overdose, though folinic acid may be used to counteract folate-related hematological effects seen in chronic exposure. Supportive care includes monitoring serum potassium and ensuring adequate fluid intake to mitigate the risk of kidney issues. Elderly patients and those with renal impairment are officially noted to be more susceptible to severe overdose effects.

Therapeutic Uses of Doctrim

What Doctrim Treats: Main Uses and Benefits

Doctrim is commonly used across conditions presenting with acute episodes of susceptible bacterial infections. This combination medicine is used in the management of infections of the urinary tract (UTIs, pyelonephritis), acute exacerbation of chronic bronchitis, and otitis media (middle ear infection), as well as specific gastrointestinal illnesses like shigellosis.

In these contexts, the medicine helps address symptom clusters that become intense or disruptive, such as the pain and urgency of bladder infections. It is also indicated for certain severe infections, including Pneumocystis jirovecii pneumonia (PJP/PCP) and toxoplasmosis, especially in immunocompromised patients.

“The primary goal is to provide supportive relief during symptomatic phases and help maintain a sense of stability when symptoms are more noticeable.”

By supporting the process of addressing the infection, the medication assists with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes.


Quick Fact: Support for Acute Discomfort

Doctrim is commonly used to help manage the burning sensation (dysuria) and urgency associated with acute, susceptible bacterial infections of the urinary tract.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Doctrim?

Official regulatory documents establish strict eligibility criteria for Doctrim (Co-trimoxazole) based on patient health status and age. The medicine is eligible for use in adults, adolescents, and children two months of age and older.


Absolute Contraindications

Doctrim is prohibited for patients with a known hypersensitivity to sulfonamides or trimethoprim, or a history of drug-induced immune thrombocytopenia. It is also contraindicated in infants under two months of age, in pregnant women at term, and in nursing mothers. Furthermore, it must not be used in patients with marked hepatic damage, severe renal insufficiency where function cannot be monitored, acute porphyria, or documented megaloblastic anemia due to folate deficiency.


Conditional Use and Restrictions

Special caution is mandated for older adults due to potential changes in drug clearance and increased susceptibility to adverse effects. Caution is also required for patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency. The drug is not indicated for the treatment of Group A beta-hemolytic streptococcal infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Doctrim (Co-trimoxazole) is documented in regulatory sources to participate in several significant interaction patterns with other medicines and substances. These interactions are categorized based on their mechanism and resulting clinical constraint.

Formal Interaction Constraints

Classification Interacting Agent Official Constraint
Contraindicated Dofetilide Prohibited co-administration due to risk of serious arrhythmias.
Avoidance Required Leucovorin Avoid concurrent use during PJP treatment due to documented increased mortality risk.

Documented Exposure and Pharmacodynamic Interactions

Co-administration with Doctrim can lead to increased plasma concentrations of several drugs due to altered metabolism or renal clearance. This includes the anti-epileptic medicine Phenytoin, the blood thinner Warfarin, and the heart medicine Digoxin, particularly in elderly patients. The combination is also associated with additive effects that increase specific risks.

  • Hyperkalaemia Risk: Concurrent use with ACE inhibitors or ARBs may lead to clinically relevant elevated potassium levels.
  • Antifolate Risk: When taken with Methotrexate or high-dose Pyrimethamine, there is an increased risk of megaloblastic anemia due to additive antifolate effects.

Substance and Population Considerations

The use of alcohol is restricted due to the potential for a disulfiram-like reaction. Furthermore, certain interactions, such as the increased risk of low platelet count (thrombocytopenia) when combined with thiazide diuretics, are specifically noted in official labels as being heightened in the elderly population.

Mechanism of Action

Doctrim's mechanism is defined by the sequential blockade of the essential bacterial folate synthesis pathway by its two active components, achieving a bactericidal effect. Sulphamethoxazole acts as a competitive inhibitor of the enzyme Dihydropteroate synthase (DHPS), and Trimethoprim inhibits the subsequent enzyme, Dihydrofolate reductase (DHFR). This coordinated, dual action severely disrupts the microbe's ability to produce Tetrahydrofolic acid (THF). The core mechanistic consequence is the rapid depletion of necessary precursors like purines and thymidylate. This molecular crisis halts cellular replication, leading to microbial cell death and the cessation of proliferation. The mechanism exploits the differential affinity for bacterial DHFR over the host's DHFR. However, the functional inhibition can be constrained by microbial strategies for bypassing the blockade, such as acquiring resistant DHPS or DHFR enzymes, which reduces the effectiveness of the enzyme inhibition.

Dosage and Administration Information

How to Use Doctrim

Doctrim, a fixed-dose combination of Trimethoprim (TMP) and Sulfamethoxazole (SMX), is administered through two established routes: oral (tablet or suspension) and intravenous (IV) infusion. The usage protocol focuses on dose quantity, frequency, duration, and patient-specific modifications.

Standard Administration and Dosing

The most common regimen for treating acute infections such as urinary tract infections (UTI) involves the Double-Strength (DS) tablet (160 mg TMP / 800 mg SMX) taken every 12 hours. In contrast, treatment for severe infections like Pneumocystis jirovecii pneumonia (PJP) involves a higher daily dose based on 15 to 20 mg/kg of the TMP component, divided into doses administered every 6 to 8 hours.

Oral preparations are typically taken with a full glass of water, and adequate fluid intake is maintained throughout the course of therapy. The IV concentrate is diluted, commonly in 5% Dextrose in Water (D5W), and administered by slow infusion over 60 to 90 minutes to ensure systemic delivery.

Usage Principle Requirement Duration
Standard Frequency Every 12 hours (B.I.D.) 5 to 14 days
High-Dose Frequency Every 6 to 8 hours (T.I.D. or Q.I.D.) 14 to 21 days

Population-Specific Adjustments

Standard protocols include dose modification based on renal function. If the patient's creatinine clearance (CrCl) is between 15 and 30 mL/min, the dose is reduced by half. Use is generally not recommended for CrCl below 15 mL/min. The medication is also not indicated for infants younger than 2 months of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Doctrim (Co-trimoxazole)


Evidence for Use in Urinary Tract Infections (UTIs) and Pyelonephritis

Doctrim was studied for use in acute UTIs, including more severe kidney infections (pyelonephritis). Research examined short-term symptom patterns in various populations, including adults and children over two months of age. These studies were conducted to assess the measurement of microbial clearance and the rate of change in symptoms (e.g., pain or urgency) as measured in clinical trials.

Numerous comparative trials reported patterns observed in the measurement of microbial clearance in both uncomplicated and complicated UTIs. Studies reported measurements of symptom resolution during the typically short treatment period of 7 to 14 days. While the evidence base for this indication is structurally categorized as High by research bodies, results apply only to the populations studied. The applicability of these findings is limited where local antimicrobial resistance to this medicine is documented as being high.


Evidence for Use in Pneumocystis jirovecii Pneumonia (PJP)

Research explored the use of Doctrim for both the measurement of acute outcomes and long-term prevention (prophylaxis) of PJP. These studies primarily took the form of Randomized Controlled Trials and Observational Cohort Studies focusing on immunocompromised individuals (like those with HIV/AIDS). Research monitored outcomes related to physiological strain, such as the rates of mortality and the incidence of related illness (morbidity), often over prolonged or indefinite observation periods.

Studies report how symptoms changed in the observed populations, noting patterns related to survival and the frequency of new PJP episodes. The evidence structure for both treatment and prevention is broadly labeled as High. However, the results apply only to the specific, high-risk populations studied. Studies frequently reported that study-limiting events was associated with participant discontinuation in some trials, indicating a practical limitation in the research setting.


Understanding Long-Term Outcomes and Durability of Effect

Clinical trials for treating acute conditions, such as UTIs and respiratory infections, involve limited follow-up durations. These short-term studies primarily focused on outcomes measured during the acute treatment phase and short-term symptom change. Conversely, research exploring prevention of specific opportunistic infections, such as PJP, often required prolonged or continuous observation. Overall, there is limited information for long-term outcomes regarding the durability of response for general, acute infections.

Key Studies & References

  1. Trimethoprim and Sulfamethoxazole: MedlinePlus Drug Information
  2. Co-trimoxazole versus placebo for shigella infection (RCT summary)

Frequently Asked Questions (FAQ)

Common questions about Doctrim (FAQ)


Q: Is Doctrim only used for the condition listed in the main description?

Official product information indicates that Doctrim is approved for treating a range of bacterial and protozoal infections beyond the most commonly discussed uses. These approved indications include urinary tract infections (UTI), shigellosis, traveler's diarrhea, and infections like Pneumocystis jirovecii pneumonia (PJP). The full scope of uses for this medicine is described in the complete regulatory labeling documents.


Q: Are there common side effects of Doctrim that usually go away on their own?

According to official product documentation, less serious side effects are generally expected to improve over time as the body adjusts to the medicine. These common and usually temporary effects can include stomach upset, nausea, or diarrhea. Regulatory guidance advises reporting any persistent or severe side effects to a healthcare provider.


Q: Is feeling tired, sleepy, or fatigued a possible side effect of Doctrim?

Official documents list unusual tiredness or weakness as a documented side effect that may be experienced while taking this medicine. This symptom is generally noted for monitoring by a healthcare professional, as its severity can vary. Official documentation specifies that this symptom is one that requires professional monitoring.


Q: How often do serious side effects associated with Doctrim actually occur?

The risk of serious adverse reactions, such as severe cutaneous adverse reactions (like Stevens-Johnson syndrome) and serious blood disorders, is categorized in regulatory documents as Very Rare. This classification indicates that these serious events occur in less than 1 out of 10,000 people who use the medicine.


Q: What are the mildest side effects reported for Doctrim?

Regulatory documents classify the most frequently documented side effects as Common. These commonly reported effects, which are the most frequently observed reactions, include headache, nausea, and diarrhea. The full spectrum of possible effects is listed in the official safety profile.


Q: I've read about a specific adverse event; how is this risk quantified in regulatory documents?

The official risk for adverse events is quantified using standardized frequency categories, such as Common, Uncommon, or Very Rare. These classifications are based on the number of cases reported across all clinical trials and post-marketing surveillance data. This system allows health authorities to communicate risk in a consistent, factual manner.


Q: Is there a list of drug classes that are known to interact with Doctrim?

Yes, regulatory documents note that Doctrim may interact with certain drug classes. These classes include blood thinners (anticoagulants), certain heart or blood pressure medicines (like ACE inhibitors), and antifolate agents (like Methotrexate). These interactions are noted as requiring professional management or monitoring.


Q: Is there a specific time of day that is suggested for taking Doctrim?

Official instructions focus on maintaining consistent drug levels by spacing doses evenly throughout the day, often at 12-hour intervals. The timing (morning or night) is less critical than adhering strictly to the prescribed interval to ensure effectiveness. Following the correct time interval is the primary focus of administration.


Q: Is Doctrim approved for use in older adults or seniors?

Yes, the medicine can be prescribed to older adults when clinically appropriate. However, official information notes that older patients are more susceptible to adverse effects, often due to changes in kidney function. Official caution statements indicate that careful monitoring is required for this population.


Q: What chronic health conditions are typically listed as contraindications for Doctrim use?

The medicine is absolutely prohibited (contraindicated) for patients with specific severe conditions, including marked liver damage and severe renal insufficiency. Other contraindications include documented megaloblastic anemia due to folate deficiency, acute porphyria, or a known hypersensitivity to the drug's components.


Q: Where can a patient find the complete, official prescribing information for Doctrim?

Patients can find the complete official prescribing information through government health and drug regulatory websites. These resources, such as DailyMed or Clinical Info maintained by the National Institutes of Health (NIH) and the FDA, contain the authoritative regulatory labels for the medicine.


Q: What should I expect if I forget to take a dose of Doctrim?

Official patient information states that the medicine is to be taken as soon as it is remembered. However, official patient information indicates that if it is near the next scheduled dose, the missed dose should be skipped. It is prohibited to take a double dose to make up for a missed one.


Q: If side effects appear, do they tend to improve or get worse over time?

Studies and official information indicate that most common side effects are temporary and tend to lessen as the body adjusts to the medication during the course of treatment. Regulatory guidance specifies contacting a healthcare provider if symptoms are persistent, severe, or concerning.


Q: Can I take common over-the-counter pain relievers, like ibuprofen or Tylenol, with Doctrim?

According to regulatory guidance and clinical data, Acetaminophen (Tylenol/Paracetamol) is generally considered safe to use with this medicine. However, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may reduce the body's ability to eliminate the trimethoprim component. Official caution statements note that this combination requires professional monitoring.


Q: Does Doctrim interact with standard daily vitamins or mineral supplements?

Due to the antifolate mechanism of action, there is a risk of additive antifolate effects when this medicine is used with supplements containing folic acid (Vitamin B9) or other antifolate agents. Regulatory documents indicate that professional review of all standard daily vitamins and supplements is necessary for safety.


Q: Does Doctrim need to be taken with a meal, or can it be taken on an empty stomach?

Official patient information indicates that the medicine can be taken either with food or on an empty stomach. Taking it with some food or a drink is generally recommended to minimize the potential for mild gastrointestinal side effects, such as stomach upset or nausea. Adequate fluid intake should always be maintained during therapy.


Q: Is it safe to crush, split, or chew the tablets/capsules of Doctrim?

For patients who have difficulty swallowing, regulatory-based guidance states that the tablets may be split or crushed and mixed in a small amount of water or soft food. Regulatory guidance stipulates that any alteration of the medicine, such as crushing or splitting, requires confirmation and instruction from a healthcare provider or pharmacist.

How should Doctrim be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for medicines containing sulfamethoxazole and trimethoprim (Doctrim) are defined by government regulatory documents to maintain drug stability and ensure public safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Range Store tablets and oral suspension at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protection The oral suspension must be protected from light. All forms must be kept in the original container.
Special Handling The intravenous solution should generally not be refrigerated to prevent precipitation.
Child Safety All forms must be stored out of the reach and sight of children.

Disposal Rules

Disposal should follow a specific regulatory hierarchy. The preferred method for discarding unused or expired product is an authorized drug take-back program. If a take-back program is unavailable, the product should be mixed with an unappealing substance (like used coffee grounds), placed in a sealed plastic bag, and thrown into the household trash. This product is not listed for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doctrim found in:

A-Z Index: